CrushSCI.com
Journal Selection & Manuscript Polishing Services
npj Breast Cancer journal cover Medicine
Back to journal directory

Review Cycle Records

npj Breast Cancer

Springer SCIE OA
2026 Emerging Zone 22025 CAS Zone 2 TOP2025 JCR Q1
123.2Average days
119.5Median days
46Fastest days
218Longest days
1672025 publications

Paper Review Records

All Paper Review Records

10 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

132 days

Proteomic signatures identify significantly different inflammatory breast tissue microenvironments depending on mammographic density or estrogen exposure

AuthorsMenikae K. Heenkenda; Annelie Abrahamsson; Peter Lundberg; Charlotta Dabrosin

Affiliations1. Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden; 2. Clinical Department of Oncology, Region Östergötland, Linköping, Sweden; 3. Clinical Department of Medical Radiation Physics, Region Östergötland, Linköping, Sweden; 4. Center for Medical Image Science and Visualization (CMIV), Linköping University, Linköping, Sweden; 5. Department of Health, Medicine, and Caring Sciences, Linköping University, Linköping, Sweden; 6. Clinical Department of Radiology, Region Östergötland, Linköping, Sweden

Source PDF DOI Publisher page
218 days

Genomic characterization of ER-positive primary tumors and corresponding relapses identifies potentially targetable alterations

AuthorsCaroline Schagerholm Stanev; Stephanie Robertson; Hosein Toosi; Emmanouil G. Sifakis; Jens Lagergren; Johan Hartman

Affiliations1. Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; 2. Division of Computational Science and Technology, KTH Royal Institute of Technology and Science for Life Laboratory, Stockholm, Sweden; 3. Department of Clinical Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm, Sweden

Source PDF DOI Publisher page
207 days

DynamicBUS: restoring temporal dynamics from static ultrasound for improved breast cancer diagnosis

AuthorsZhikai Yang; Yaofang Liu; Tianhao Bai; Ander Biguri; Haoyuan Chen; Yonghao Li; Carola-Bibiane Schönlieb; Örjan Smedby; Raymond Chan; Rodrigo Moreno

Affiliations1. Department of Biomedical Engineering and Health Systems, KTH Royal Institute of Technology, Stockholm, Sweden; 2. City University of Hong Kong, Hong Kong, China; 3. COCHE, Hong Kong, China; 4. Department of Ultrasound, Aviation General Hospital, Beijing, China; 5. University of Cambridge, Cambridge, UK; 6. School of Biomedical Engineering & State Key Laboratory of Advanced Medical Materials and Devices, ShanghaiTech University, Shanghai, China; 7. Lingnan University, Hong Kong, China; 8. Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden

Source PDF DOI Publisher page
113 days

Genome-wide DNA methylation profiling of triple-negative breast cancer uncovers epigenetic biomarkers of tumor identity and the immune microenvironment

AuthorsIñaki Sasiain; Deborah F. Nacer; Mats Jönsson; Johan Vallon-Christersson; Anita Grigoriadis; Mattias Aine; Johan Staaf

Affiliations1. Division of Translational Cancer Research, Department of Laboratory Medicine, Lund University, Lund, Sweden; 2. Lund University Cancer Center, Lund University, Lund, Sweden; 3. Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden; 4. Cancer Bioinformatics, Breast Cancer Now Unit, Comprehensive Cancer Centre, Faculty of Life Sciences and Medicine, King’s College London, London, UK; 5. Spatial Biology Facility, Faculty of Life Sciences and Medicine, King’s College London, London, UK

Source PDF DOI Publisher page
96 days

Circulating tumor DNA as an arbitrator for postmastectomy radiotherapy: bridging molecular residual disease and locoregional control

AuthorsGai Liang; Qu Zhang; Mengting Yuan; Guojun Yao; Feng Yuan

Affiliations1. Department of Radiation Oncology, Hubei Cancer Hospital, TongJi Medical College, Huazhong University of Science and Technology, Wuhan, China; 2. Department of Breast Surgery, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, National Key Clinical Specialty, Hubei Provincial Clinical Research Center for Breast Cancer, Wuhan Clinical Research Center for Breast Cancer, Wuhan, China

Source PDF DOI Publisher page
46 days

Multi-omics analysis in suspected hereditary breast and ovarian cancer cases reveals novel candidate susceptibility factors

AuthorsB. Aldrige Allister; Winfried Hofmann; Jonathan L. Lühmann; Björn Sander; Lena Wendeburg; Gunnar Schmidt; Bernd Auber; Susanne Morlot; Hannah Wallaschek; Nataliya di Donato; Brigitte Schlegelberger; Monika M. Golas; Doris Steinemann

Affiliations1. Department of Human Genetics, Hannover Medical School, Hannover, Germany; 2. Institute of Pathology, Hannover Medical School, Hannover, Germany; 3. Institute of Human Genetics, University Hospital Augsburg and Faculty of Medicine, University of Augsburg, Augsburg, Germany; 4. Comprehensive Cancer Center Augsburg, University Hospital Augsburg, Augsburg, Germany

Source PDF DOI Publisher page
155 days

Novel method for risk stratification of radiation-induced breast fibrosis: subgroup hypothesis verified by machine learning

AuthorsAhmad Sami; Petra Seibold; Carsten Sticht; Frank A. Giordano; Marlon R. Veldwijk; Carsten Herskind

Affiliations1. Cellular and Molecular Radiation Oncology Lab, Dept. of Radiation Oncology, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; 2. DKFZ Hector Cancer Institute at University Medicine Mannheim, Heidelberg, Germany; 3. Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; 4. Core Facility Platform Mannheim (CFPM), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; 5. Department of Radiation Oncology, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; 6. Mannheim Institute of Intelligent Systems in Medicine (MIISM), Heidelberg University, Mannheim, Germany

Source PDF DOI Publisher page
57 days

SERENA-6 interpretation and clinical implications: intercepting endocrine resistance in metastatic breast cancer

AuthorsFrançois-Clement Bidard; Carlos Barrios; Giampaolo Bianchini; Adam M. Brufsky; Stephen Chia; Javier Cortes; Massimo Cristofanilli; Giuseppe Curigliano; Shaheenah Dawood; Peter A. Fasching; Lorenzo Gerratana; Antonio Giordano; Michail Ignatiadis; Hiroji Iwata; Wolfgang Janni; Elgene Lim; Kevin Kalinsky; Cynthia X. Ma; Erica L. Mayer; Arielle J. Medford; Jason A. Mouabbi; Joyce O’Shaughnessy; Yeon Hee Park; Javier Pascual; Pedram Razavi; Sarah Sammons; José Luis Sandoval; Luisana Sisca; Paolo Tarantino; Seth A. Wander; Gustavo Werutsky; Nicholas A. Turner

Affiliations1. Department of Medical Oncology, Inserm CIC 2501, Institut Curie, Paris, France; 2. UVSQ, Universite Paris-Saclay, Paris, France; 3. Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil; 4. Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy; 5. School of Medicine and Surgery, Vita-Salute San Raffaele University, Milan, Italy; 6. UPMC Magee-Womens Hospital, Pittsburgh, USA; 7. Division of Malignant Hematology/Medical Oncology, Department of Internal Medicine, University of Pittsburgh School of Medicine, Pittsburgh, USA; 8. BC Cancer – Vancouver Cancer Centre, Vancouver, Canada; 9. International Breast Cancer Center (IBCC), Pangaea Oncology, Quirón Group, Barcelona, Spain; 10. IOB Madrid, Institute of Oncology, Hospital Beata María Ana, Madrid, Spain; 11. Department of Medicine, Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid, Madrid, Spain; 12. Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain and Ridgewood, Ridgewood, USA; 13. Department of Medicine, Division of Hematology-Oncology, Weill Cornell Medicine, New York, USA; 14. Department of Oncology and Hemato-Oncology, University of Milano, Milano, Italy; 15. Istituto Europeo di Oncologia, IRCCS, Milano, Italy; 16. Mediclinic Hospital, Dubai, United Arab Emirates; 17. Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai, United Arab Emirates; 18. Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany; 19. Department of Medical Oncology, CRO di Aviano, National Cancer Institute, IRCCS, Aviano, Italy; 20. Department of Medicine, University of Udine, Udine, Italy; 21. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; 22. Harvard Medical School, Boston, USA; 23. Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B.), Université libre de Bruxelles (ULB), Brussels, Belgium; 24. Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan; 25. Department of Obstetrics and Gynecology, University Hospital Ulm, Ulm, Germany; 26. Garvan Institute of Medical Research, Darlinghurst, Australia; 27. Faculty of Medicine, St Vincent’s Clinical School, UNSW Sydney, Darlinghurst, Australia; 28. St Vincent’s Hospital, Darlinghurst, Australia; 29. Department of Hematology and Oncology, Winship Cancer Institute of Emory University, Atlanta, USA; 30. Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, USA; 31. Mass General Cancer Center, Boston, USA; 32. Division of Cancer Medicine, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA; 33. Baylor University Medical Center, Dallas, USA; 34. Texas Oncology, Dallas, USA; 35. Sarah Cannon Research Institute, Dallas, USA; 36. Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; 37. Medical Oncology Department, Hospital Universitario Virgen de la Victoria, Malaga, Spain; 38. GEICAM Spanish Breast Cancer Group, Madrid, Spain; 39. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA; 40. Translational Oncology Partnership Program, Memorial Sloan Kettering Cancer Center, New York, USA; 41. Dana-Farber Brigham Cancer Center, Boston, USA; 42. Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; 43. Dana-Farber Cancer Institute, Boston, USA; 44. Department of Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland; 45. Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Rome, Italy; 46. Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy; 47. Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, USA; 48. Department of Medical Oncology, Mass General Brigham Cancer Institute, Harvard Medical School, Boston, USA; 49. Royal Marsden NHS Foundation Trust, London, UK

Source PDF DOI Publisher page
82 days

The clinical relevance of apocrine morphology in breast cancer depends on the estrogen receptor status

AuthorsKei Kawashima; Masanori Oshi; Akimitsu Yamada; Kazutaka Narui; Zunairah Shah; Thaer Khoury; Itaru Endo; Kazuaki Takabe

Affiliations1. Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, USA; 2. Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan; 3. Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Japan; 4. Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, USA; 5. Department of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, USA; 6. Department of Surgery, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, the State University of New York, Buffalo, USA; 7. Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan; 8. Department of Breast Surgery and Oncology, Tokyo Medical University, Tokyo, Japan; 9. Department of Breast Surgery, Fukushima Medical University, Fukushima, Japan

Source PDF DOI Publisher page
126 days

Targeted axillary dissection in breast cancer patients: a systematic review and meta-analysis

AuthorsMohammed. N. Abdelaziz; Sagad O. O. Mohamed; Mohammed Hesham Nagi; Ibrahim Saleh Alawadi; Youstina Mohsen; Sohaila Essam Ibrahim; Radwa M. Abdelsattar; Asmaa. N. Abdelaziz; Mohamed Yasser; Sherif Wael; Hend A. Abdelgawad; Magdy Shehab; Khaled M. Abdelwahab; Omar Hamdy

Affiliations1. Faculty of Medicine, Mansoura University Hospital, Mansoura, Egypt; 2. University of Khartoum, Khartoum, Sudan; 3. Faculty of medicine, Kasr Alainy, Cairo University, Cairo, Egypt; 4. Surgical Oncology Department, Oncology Centre, Mansoura University, Mansoura, Egypt

Source PDF DOI Publisher page

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review96.4 days

Median77 days

Contact CrushSCI

Contact CrushSCI

Leave your contact details so we can discuss your manuscript, editing needs, and submission plan.

Selected service: Paper Editing Service

Or leave your contact details

WhatsApp, Telegram, WeChat, and email are all optional, but at least one is required. Once received, we will contact you as soon as possible.